One year of treatment with Elizaria — a drug similar to the U.S.-approved therapy Soliris (eculizumab) — for atypical hemolytic uremic syndrome (aHUS) was found to be safe and to help stabilize kidney function among people with the genetic disease taking part in a study in Russia. The results…
Discussion
Treatment with Ultomiris (ravulizumab) successfully prevented disease recurrence in a middle-aged man whose atypical hemolytic uremic syndrome (aHUS) was linked to a novel mutation — one believed to put him at a high risk for relapse — in the CFH gene, a case report from Japan shows. During the…
Becoming educated and informed about aHUS is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnist’s words of wisdom to help you along on your aHUS journey.
There is no cure for aHUS yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
